| 2019-08-14 07:35:05|
DCPH 07:35 08/14 08/14/19
Deciphera price target raised to $29 from $20 at SVB Leerink
SVB Leerink analyst Andrew Berens raised his price target for Deciphera to $29 from $20 following positive top-line data from the company's Phase 3 INVICTUS trial that exceeded his expectations, in addition to favorable updates to the Phase 1 ripretinib data. The analyst reiterates an Underperform rating on the shares.